Oryzon Genomics S.A. (0RDB.L) • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0RDB.L in your mock portfolio yet.
The company is currently loss-making, as reflected in its negative EPS and negative PE ratio. This implies that, on a pure earnings basis, Oryzon Genomics S.A. is not yet generating sustainable profitability, which is typical for early-stage or clinical-stage biotech but still a financial risk factor. Without evidence of improving earnings trends, the financial profile leans negative from a traditional valuation perspective.
The stock trades at €2.75, modestly up 0.5% over the last month, suggesting a stable to slightly positive short-term trend. Technically, the price is well above the 200-day moving average of €2.06, which is generally a constructive signal indicating a longer-term uptrend or recovery. Despite weak fundamentals, the technical setup currently leans positive, implying market participants are willing to look through near-term losses.
Website traffic of about 8,910 visitors per month and 11,296 LinkedIn followers indicate a modest but established digital and professional presence. However, zero current job openings suggest limited near-term expansion or hiring momentum, which tempers growth expectations. Overall, alternative data are stable but not strongly indicative of accelerating business activity.
The stock exhibits a constructive technical profile, trading well above its 200-day moving average, but this is offset by ongoing losses and a lack of clear profitability, leaving the overall picture balanced. Alternative data show a stable but not rapidly expanding footprint, with no strong signals of imminent operational scaling. Taken together, the outlook appears neutral, with upside dependent on future execution and catalysts rather than current financial strength.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started